Market Newsdesk

WEST PALM BEACH, Fla., Jan. 14, 2026 (GLOBE NEWSWIRE) — LXP Industrial Trust (“LXP”) (NYSE:LXP), a real estate investment trust focused on Class A warehouse and distribution real estate investments, today announced it has closed a $600 million senior unsecured revolving credit facility. The facility amends and restates LXP’s previous unsecured revolving credit facility.

The new revolving credit facility matures on January 31, 2030, with the option to extend the maturity for two successive six-month terms or one twelve-month term, at LXP’s discretion, subject to certain conditions. The facility provides for an interest rate of SOFR plus 77.5 basis points, based on LXP’s current consolidated leverage ratio and credit ratings, reduced from SOFR plus 95 basis points under the previous facility. The facility also provides for a facility fee of 15 basis points of total commitments, reduced from 20 basis points under the previous facility.

LXP also announced the refinancing of its $250 million unsecured term loan with an initial maturity date of January 31, 2029, with two one-year extension options at LXP’s discretion, subject to certain conditions. The term loan provides for an interest rate of SOFR plus 85 basis points, based on the Company’s current consolidated leverage ratio and credit ratings, reduced from 110 basis points under the previous facility.

Nathan Brunner, Chief Financial Officer of LXP, commented, “The new debt facilities extend our debt maturity profile and reduce our interest costs, further strengthening our balance sheet and increasing our financial flexibility. This builds on the balance sheet progress we achieved in 2025, including reducing leverage to approximately five times net debt to Adjusted EBITDA, as recognized by the recent action by S&P Global Ratings to revise LXP’s outlook to positive. We appreciate the ongoing support of our bank group and their continued confidence in LXP.”

KeyBanc Capital Markets, Inc., Wells Fargo Securities, LLC and Regions Capital Markets served as the Joint Lead Arrangers and Joint Bookrunners. KeyBank National Association is the Administrative Agent and Wells Fargo Bank, National Association and Regions Bank served as Syndication Agents. Bank Of America, N.A., Citizens Bank, N.A., Mizuho Bank, Ltd., JPMorgan Chase Bank, N.A., PNC Bank, National Association, TD Bank, N.A. and U.S. Bank National Association acted as Documentation Agents, with Associated Bank, National Association also participating in the transaction.

ABOUT LXP INDUSTRIAL TRUST

LXP Industrial Trust (NYSE: LXP) is a publicly traded real estate investment trust (REIT) focused on Class A warehouse and distribution investments in 12 target markets across the Sunbelt and lower Midwest. LXP seeks to expand its warehouse and distribution portfolio through acquisitions, build-to-suit transactions, sale-leaseback transactions, development projects and other transactions. For more information, including LXP’s Quarterly Supplemental Information package, or to follow LXP on social media, visit www.lxp.com.

Contact:

Investor or Media Inquiries for LXP Industrial Trust:
Heather Gentry, Executive Vice President of Investor Relations
LXP Industrial Trust
Phone: (212) 692-7200 E-mail: [email protected]

This release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements, including, but not limited to, statements regarding the use of proceeds from the sale. Such forward-looking statements involve known and unknown risks, uncertainties and other factors not under LXP’s control which may cause actual results, performance or achievements of LXP to be materially different from the results, performance, or other expectations implied by these forward-looking statements. These factors include, but are not limited to, those factors and risks detailed in LXP’s periodic filings with the SEC. Except as required by law, LXP undertakes no obligation to publicly release the results of any revisions to those forward-looking statements which may be made to reflect events or circumstances after the occurrence of unanticipated events.

SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) — NeoVolta Inc. (NASDAQ: NEOV) (“NeoVolta” or the “Company”), a U.S.-based energy technology company delivering scalable energy storage solutions, today announced the formation of NeoVolta Power, LLC, a joint venture established to develop a U.S. battery energy storage system (BESS) manufacturing platform in Pendergrass, Georgia. The launch of domestic manufacturing capacity when complete will represent a transformational expansion of NeoVolta’s business model, positioning the Company to serve the utility-scale and commercial & industrial (C&I) energy storage markets as a U.S. manufacturer.

The Georgia facility is designed for 2 GWh of initial annual production capacity, scalable to up to 8 GWh, and is expected to begin mass production in mid-2026. Located along the I-85 corridor, the facility will initially focus on prismatic-cell battery pack assembly and DC container integration, supporting approximately 89 production personnel at steady-state initial capacity.

This announcement marks a step-change in NeoVolta’s scale and strategic positioning. The Company believes the establishment of domestic BESS manufacturing capacity materially expands its addressable market, growth profile, and long-term relevance, and warrants a closer evaluation of NeoVolta’s opportunity set.

Illustrative Revenue Potential

Industry analyses, including from the U.S. National Renewable Energy Laboratory (NREL), indicate that utility-scale and C&I battery energy storage systems in active U.S. markets can generate approximately $200 per kilowatt-hour of installed capacity, depending on configuration and commercial structure.

At an illustrative level, 2 GWh of annual production at an average realized value of $200 per kilowatt-hour would represent approximately $400 million of annual revenue potential at full utilization. This illustrative example is not a forecast or projection and is provided solely to convey the scale of the opportunity. Actual results may differ materially based on product mix, customer contracts, pricing, capacity utilization, market conditions, and other factors.

This illustrative example is provided to highlight the order of magnitude of the opportunity associated with domestic BESS manufacturing and does not constitute financial or revenue guidance. Broader industry forecasts from sources including BloombergNEF, NREL, and Wood Mackenzie project the total U.S. battery energy storage TAM, spanning utility-scale, residential, C&I, and related services, to expand to approximately $45 billion annually by 2030. By establishing domestic manufacturing focused on utility-scale and C&I systems, NeoVolta Power positions the Company to address a significantly larger share of this rapidly growing market.

“This transformative joint venture with PotisEdge and LONGi represents a major step forward for NeoVolta, positioning us as a vertically integrated leader in the fast-growing energy storage sector. By launching domestic BESS manufacturing, we’re directly addressing surging demand in utility-scale and C&I markets, enabling scalable, reliable solutions for grid stability, peak load management, and high-growth applications,” said Ardes Johnson, Chief Executive Officer of NeoVolta.

NeoVolta holds a 60% controlling interest in the joint venture, NeoVolta Power, LLC, and will oversee product strategy, commercialization, and customer engagement. Governance is structured through a five-member board of managers, three of whom are appointed by NeoVolta. PotisEdge holds a 20% ownership interest and contributes deep expertise in large-scale BESS manufacturing, equipment installation, commissioning, and production ramp support. The remaining 20% is held by a group of strategic investors providing additional technical and operational support. Based on this ownership and governance structure, NeoVolta expects to consolidate the joint venture’s financial results in its consolidated financial statements under U.S. GAAP, with minority interests reflected as non-controlling interests, subject to final agreement terms and applicable accounting standards.

Strategic Manufacturing Platform

Initial production is expected to be weighted toward utility-scale systems, with C&I systems representing an increasing share as demand grows. The platform is designed to support multiple system configurations and product formats to meet evolving market requirements.

Strategic Partnership with Global Renewable Energy Leaders

The joint venture brings together three complementary energy technology leaders: NeoVolta, PotisEdge, and LONGi Green Energy.

PotisEdge, a globally recognized leader in BESS manufacturing and now part of LONGi Green Energy, holds a 20% ownership interest in the JV and contributes deep expertise in large-scale battery manufacturing, including equipment installation, commissioning, and production ramp support, based on proven systems deployed internationally.

LONGi, one of the world’s largest renewable energy companies and the global leader in solar manufacturing, is the majority owner of PotisEdge as part of its strategic expansion into energy storage. LONGi’s involvement reflects broader industry convergence across solar, storage, and integrated clean-energy solutions, and underscores the strategic relevance of the JV within the global renewable energy ecosystem.

Together, the three companies combine NeoVolta’s U.S. market leadership and product strategy, PotisEdge’s advanced BESS manufacturing systems, and LONGi’s global scale, execution discipline, and energy-transition vision, creating a domestic manufacturing platform designed for scale, quality, and long-term growth.

Partner Perspectives

“PotisEdge is proud to partner with NeoVolta in building a U.S. battery manufacturing platform designed for scale and long-term growth,” said Minjie, Founder and Chief Technology Officer of PotisEdge. “As a minority owner, we are contributing our manufacturing experience, systems, and technical capabilities to support efficient execution and a successful production ramp for utility-scale and C&I energy storage solutions.”

“LONGi’s strategic expansion into energy storage reflects our commitment to delivering integrated, scalable clean-energy solutions,” said Eric Luo, Group Vice President and President of North America at LONGi Green Energy. “By aligning PotisEdge’s technology leadership with NeoVolta’s U.S. market expertise, this joint venture brings together complementary strengths to serve the next phase of growth in renewable energy infrastructure.”

Financing and Capital Support

The formation and initial development of the joint venture are supported by capital commitments and phased funding aligned with manufacturing milestones. Funding is expected to be provided through a combination of equity and debt, anchored by Infinite Grid Capital.

NeoVolta announced a $13 million private placement in November 2025, anchored by Infinite Grid Capital, providing near-term capital to support initial JV funding requirements and general corporate purposes. As capacity ramps, the JV is structured to pursue project-level debt financing, incentive monetization, and other customary funding sources for U.S. manufacturing facilities, providing flexibility to support expansion beyond initial production levels.

Upcoming Milestones

Key anticipated milestones include:
• Execution of technical and management services agreements
• Acquisition and installation of manufacturing equipment
• Initial production ramp in mid-2026
• Planning for expansion beyond 2 GWh of annual capacity

NeoVolta expects to provide updates as these milestones are achieved.

About NeoVolta

NeoVolta is an innovator in energy storage solutions dedicated to advancing reliable, high-performance power infrastructure for residential, commercial, and utility applications. With a focus on scalable technology, domestic manufacturing, and strategic partnerships, NeoVolta is positioned to support the accelerating transition toward resilient energy systems.

For more information, visit www.neovolta.com.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding manufacturing capacity, production timelines, market opportunity, revenue potential, and future operations. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in the Company’s most recently filed Form 10-K filed with the Securities and Exchange Commission (“SEC”) and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Contacts

NEOV Investors

Alliance Advisors IR
[email protected]  

NEOV Media

Email: [email protected]
Phone: 800-364-5464

RESTON, Va., Jan. 14, 2026 (GLOBE NEWSWIRE) — Lightbridge Corporation (“Lightbridge” or the “Company”) (Nasdaq: LTBR), an advanced nuclear fuel technology company, today announced that the Company’s management team will participate in the following investor conferences and events:

28th Annual Needham Growth Conference on January 14 – New York City

Lightbridge President and CEO Seth Grae will deliver a presentation on Wednesday, January 14 at 4:30 p.m. Eastern Time. A live webcast of the presentation will be available at: https://wsw.com/webcast/needham148/ltbr/2265900. A replay will also be available on the Company’s YouTube channel at: https://www.youtube.com/@lightbridgecorporation.

Global Cleantech Investor Gala & Award Ceremony on January 19 – Davos, Switzerland

Mr. Grae will deliver a presentation titled “The Need for Nuclear” on January 19 at 8:20 p.m. Central European Time.

Nuclear Energy Institute’s Nuclear Financing Summit on January 28 – New York City

Mr. Grae will be a panelist for the panel discussion titled “The New Nuclear Fuel Cycle: Technology, Supply, and Recycling Opportunities” on January 28 at 2:30 p.m. Eastern Time.

The 3rd World Nuclear SMR & Advanced Reactor Congress 2026 on February 10-11 – London, U.K.

Mr. Grae will deliver a keynote presentation titled “Advanced Fuels for Existing Reactors and for New SMRs” and will be a panelist in the panel discussion titled “Scaling Europe’s SMR Ecosystem” on February 11.

About Lightbridge Corporation

Lightbridge Corporation (NASDAQ: LTBR) is focused on developing advanced nuclear fuel technology essential for delivering abundant, zero-emission, clean energy and providing energy security to the world. The Company is developing Lightbridge Fuel™, a proprietary next-generation nuclear fuel technology for existing light water reactors and pressurized heavy water reactors, significantly enhancing reactor safety, economics, and proliferation resistance. The Company is also developing Lightbridge Fuel for new small modular reactors (SMRs) to bring the same benefits plus load-following with renewables on a zero-carbon electric grid.

Lightbridge has entered into two long-term framework agreements with Battelle Energy Alliance LLC, the United States Department of Energy’s operating contractor for Idaho National Laboratory, the United States’ lead nuclear energy research and development laboratory. DOE’s Gateway for Accelerated Innovation in Nuclear program has twice awarded Lightbridge to support the development of Lightbridge Fuel over the past several years. Lightbridge is participating in two university-led studies through the DOE Nuclear Energy University Program at Massachusetts Institute of Technology and Texas A&M University. An extensive worldwide patent portfolio backs Lightbridge’s innovative fuel technology. Lightbridge is included in the Russell Microcap® Index. For more information, please visit www.ltbridge.com.

To receive Lightbridge Corporation updates via e-mail, subscribe at 


https://www.ltbridge.com/investors/news-events/email-alerts

Lightbridge is on YouTube. Subscribe to access past demonstrations, interviews, and other video content at 


https://www.youtube.com/@lightbridgecorporation

Lightbridge is on X (formerly Twitter). Sign up to follow 


@LightbridgeCorp


at


http://twitter.com/lightbridgecorp


.

Forward Looking Statements

With the exception of historical matters, the matters discussed herein are forward-looking statements. These statements are based on current expectations on the date of this news release and involve a number of risks and uncertainties that may cause actual results to differ significantly from such estimates. The risks include, but are not limited to: Lightbridge’s ability to commercialize its nuclear fuel technology; the degree of market adoption of Lightbridge’s product and service offerings; Lightbridge’s ability to fund general corporate overhead and outside research and development costs; market competition; our ability to attract and retain qualified employees; dependence on strategic partners; demand for fuel for nuclear reactors; Lightbridge’s ability to manage its business effectively in a rapidly evolving market; the availability of nuclear test reactors and the risks associated with unexpected changes in Lightbridge’s fuel development timeline; the increased costs associated with metallization of Lightbridge’s nuclear fuel; public perception of nuclear energy generally; changes in the political environment; risks associated with war in Europe; changes in the laws, rules and regulations governing Lightbridge’s business; development and utilization of, and challenges to, Lightbridge’s intellectual property; risks associated with potential shareholder activism; potential and contingent liabilities; as well as other factors described in Lightbridge’s filings with the Securities and Exchange Commission (the “SEC”). Lightbridge does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise, except as required by law. Readers are cautioned not to put undue reliance on forward-looking statements.

A further description of risks and uncertainties can be found in Lightbridge’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in its other filings with the SEC, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Statements”, all of which are available at


http://www.sec.gov/


and


www.ltbridge.com


.

Investor Relations Contact:

Matthew Abenante, IRC
Director of Investor Relations
Tel: +1 (347) 947-2093
[email protected]

TERRE HAUTE, Ind., Jan. 14, 2026 (GLOBE NEWSWIRE) — Hallador Energy Company (Nasdaq: HNRG), today announced the pricing of an underwritten public offering of 2,777,778 shares of its common stock at a price to the public of $18.00 per share. The total gross proceeds from the offering to Hallador are expected to be approximately $50 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Hallador granted the underwriters a 30-day option to purchase up to an additional 416,666 shares of its common stock. The closing of the offering is expected to occur on or about January 15, 2026, subject to the satisfaction of customary closing conditions.

Hallador intends to use the net proceeds from the offering for general corporate purposes, which may include funding certain initial financial commitments to reserve equipment necessary to support Hallador’s planned additional natural gas generating facility.

Texas Capital Securities is acting as sole bookrunner for the offering. Northland Capital Markets and A.G.P./Alliance Global Partners are acting as co-managers for the offering.

The securities described above are being offered by Hallador pursuant to an automatic shelf registration statement on Form S-3 that became automatically effective upon its filing with the Securities and Exchange Commission (the “SEC”) on January 13, 2026.

The securities will be offered only by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. A preliminary prospectus supplement relating to this offering has been filed with the SEC and a final prospectus supplement relating to this offering will be filed with the SEC. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the offering, as well as copies of the final prospectus supplement, when available, may be obtained from TCBI Securities, Inc., d/b/a Texas Capital Securities, Attention: Prospectus Department, 2000 McKinney Avenue, Suite 700, Dallas, TX 75201 or by email at [email protected]. Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the website of the SEC at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer or sale will be made only by means of Hallador’s prospectus supplement and prospectus forming part of the effective registration statement relating to these securities.

About Hallador

Hallador Energy Company (Nasdaq: HNRG) is a vertically-integrated Independent Power Producer (IPP) based in Terre Haute, Indiana. Hallador has two core businesses: Hallador Power Company, LLC, which produces electricity and capacity at its one Gigawatt (GW) Merom Generating Station, and Sunrise Coal, LLC, which produces and supplies fuel to the Merom Generating Station and other companies.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Statements that are not strictly historical statements constitute forward-looking statements and may often, but not always, be identified by the use of such words such as “expects,” “believes,” “intends,” “anticipates,” “plans,” “estimates,” “guidance,” “target,” “potential,” “possible,” or “probable” or statements that certain actions, events or results “may,” “will,” “should,” or “could” be taken, occur or be achieved. Forward-looking statements include, without limitation, those relating to the public offering, the closing and the intended use of proceeds, and Hallador’s planned additional natural gas generating facility. Forward-looking statements are based on current expectations and assumptions and analyses made by Hallador and its management in light of experience and perception of historical trends, current market conditions and expected future developments, as well as other factors appropriate under the circumstances that involve various risks and uncertainties that could cause actual results to differ materially from those reflected in the statements. These risks include, but are not limited to, those set forth in Hallador’s annual report on Form 10-K for the year ended December 31, 2024, subsequent quarterly reports on Form 10-Q and other SEC filings. Hallador undertakes no obligation to revise or update publicly any forward-looking statements except as required by law.

Investor Relations Contact:

Sean Mansouri, CFA
Elevate IR
(720) 330-2829
[email protected]

PITTSBURGH, Pa., Jan. 14, 2026 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos” or the “Company”), an American energy company and the leading innovator in designing, sourcing, manufacturing, and providing zinc-based battery energy storage systems (BESS), today announced the launch of Eos Indensity™—and invites you to experience it first during an unveiling event happening today at 8:30 a.m. ET. Register now and be part of the future of energy storage.

Eos Indensity™ is a breakthrough architecture designed to transform how energy storage scales for the real world. It’s engineered with Spatial Intelligence, an innovative system design framework developed by the team at Eos that considers the built, human, and natural environments where power is needed most. Indensity is an architecture that rises to every site-specific challenge—setting new standards for density, scale, flexibility, and safety while building on Eos’ proven Z3™ module and zinc-powered Znyth™ technology that continues to power the Eos Cube solution.

At the center of it all is the Eos Indensity Core™—a modular, stackable building block that unlocks density by leveraging all three dimensions of a site. By reaching upward as well as outward, Indensity adapts to virtually any footprint, making gigawatt-scale storage achievable where it wasn’t before. Each Core integrates Z3 battery modules, Eos DawnOS™ advanced controls, onboard cooling, and power management in a compact, self-contained design that’s easy to place, fast to connect, and built for real-world performance.

“Indensity is more than a product—it’s a turning point,” said Joe Mastrangelo, Chief Executive Officer of Eos. “We’ve taken everything we’ve learned over 15 years and built a system that answers the toughest questions in energy storage: How do you scale responsibly? How do you deliver flexibility without compromise? How do you make storage safe enough to sit next to the assets that power modern life? The idea of what we call Spatial Intelligence—thinking deeply about and designing for the daily needs and realities of the places our storage would go—that was our team’s guiding star, and Indensity is our answer. And it’s ready now.”

What makes Indensity different?

• Next-level Density: Redefining expectations of battery storage capacity with a compact, stackable, modular design that targets 1 GWh per acre—roughly 4 times that of most other technologies.
• Breakthrough Scale: Self-contained, weather-ready Indensity Core units with plug-and-play electrical and communications simplify installation—even in previously unusable spaces.
• Extraordinary Flexibility: Supports 4-16+ hour durations, handles complex cycling with millisecond-fast response, and adapts to demanding applications like AI-driven data centers.
• Exceptional Safety: Non-flammable zinc chemistry, recyclable components, and advanced cybersecurity controls make Indensity safe enough for mission-critical sites.
• Limitless Potential: Deploy near data centers, military bases, and urban infrastructure—removing constraints and unlocking progress.

Indensity is designed for a future where electrification accelerates, AI drives unpredictable demand, and power systems face unprecedented strain—delivering storage that performs in the field, scales responsibly, and strengthens the backbone of modern economies.

Don’t miss your chance to see Indensity first. Join Eos for the official unveiling today at 8:30 a.m. ET. This is your opportunity to hear directly from Eos leadership, learn about the breakthrough architecture, and understand how Indensity sets a new standard for battery energy storage. Secure your spot now to attend the event.

About Eos Energy Enterprises

Eos is accelerating the shift to American energy independence with positively ingenious solutions that transform how the world stores power. The Company’s BESS features the innovative Znyth™ technology, a proven chemistry with readily available non-precious earth components, that is the pre-eminent safe, non-flammable, secure, stable, and scalable alternative to conventional lithium-ion technology. The Company’s BESS is ideal for utility-scale, microgrid, commercial, and industrial long-duration energy storage applications (i.e., 4 to 16+ hours) and provides customers with significant operational flexibility to cost effectively address current and future increased grid demand and complexity. For more information about Eos (NASDAQ: EOSE), visit eose.com.

Forward Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements that refer to outlook, projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are based on our management’s beliefs, as well as assumptions made by, and the information currently available to, them. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected.

Factors which may cause actual results to differ materially from current expectations include, but are not limited to: changes adversely affecting the business in which we are engaged; our ability to forecast trends accurately; our ability to generate cash, service indebtedness and incur additional indebtedness; our ability to achieve the operational milestones on the delayed draw term loan; our ability to raise financing in the future; risks associated with the credit agreement with Cerberus, including risks of default, dilution of outstanding Common Stock, consequences for failure to meet milestones and contractual lockup of shares; our customers’ ability to secure project financing; the amount of final tax credits available to our customers or to Eos pursuant to the Inflation Reduction Act; the timing and availability of future funding under the Department of Energy Loan Facility; our ability to continue to develop efficient manufacturing processes to scale and to forecast related costs and efficiencies accurately; fluctuations in our revenue and operating results; competition from existing or new competitors; our ability to convert firm order backlog and pipeline to revenue; risks associated with security breaches in our information technology systems; risks related to legal proceedings or claims; risks associated with evolving energy policies in the United States and other countries and the potential costs of regulatory compliance; risks associated with changes to the U.S. trade environment; our ability to maintain the listing of our shares of common stock on NASDAQ; our ability to grow our business and manage growth profitably, maintain relationships with customers and suppliers and retain our management and key employees; risks related to the adverse changes in general economic conditions, including inflationary pressures and increased interest rates; risk from supply chain disruptions and other impacts of geopolitical conflict; changes in applicable laws or regulations; the possibility that Eos may be adversely affected by other economic, business, and/or competitive factors; other factors beyond our control; risks related to adverse changes in general economic conditions; and other risks and uncertainties.

The forward-looking statements contained in this press release are also subject to additional risks, uncertainties, and factors, including those more fully described in the Company’s most recent filings with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K and subsequent reports on Forms 10-Q and 8-K. Further information on potential risks that could affect actual results will be included in the subsequent periodic and current reports and other filings that the Company makes with the Securities and Exchange Commission from time to time. Moreover, the Company operates in a very competitive and rapidly changing environment, and new risks and uncertainties may emerge that could have an impact on the forward-looking statements contained in this press release.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

 Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg

Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026

Internal Discovery Strategy Progressing Efforts Focused on Inflammation, Neuro-inflammation and Neuro-degenerative Diseases With Novel Targets in Clinically Validated Pathways

Cash Runway to End of 2028 Provides Funding Through Key Value Inflection Points

WATERTOWN, Mass., Jan. 14, 2026 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today outlined milestones through 2028 and highlighted recent achievements.

“We begin 2026 with compelling opportunities ahead, anchored by cemsidomide’s path to become a foundational medicine for multiple myeloma by reaching patients across multiple lines of therapy. As we prepare to initiate two cemsidomide trials in the coming months, we believe the emerging data exploring the class in combination with BiTE therapies derisks our strategy to rapidly advance cemsidomide through registrational development,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “We are equally excited about our new discovery strategy that leverages a decade of learnings in the TPD field as well as the strengths of our platform to address unmet needs for inflammation, neuro-inflammation and neuro-degenerative diseases by degrading novel targets that modulate validated inflammatory pathways. Our strong balance sheet provides cash runway through key inflection points, keeping us positioned to advance our portfolio and create transformative medicines for patients.”

Anticipated Key Strategic Milestones


C4T’s vision is to become a fully integrated biopharmaceutical company leveraging the benefits of targeted protein degradation across drug discovery, clinical development and commercialization to create and deliver breakthrough therapies for patients. To achieve this vision, C4T’s strategy centers around rapidly advancing cemsidomide to become the IKZF1/3 degrader of choice across lines of therapy and progressing its early portfolio of high-value degraders pursuing novel targets. The following anticipated key strategic milestones through 2028 support this strategy.

Cemsidomide


Relapsed/Refractory Multiple Myeloma:
Fourth Line or Later

• In Q1 2026, initiate the Phase 2 MOMENTUM trial of cemsidomide and dexamethasone and complete enrollment within 12 months.
• In mid-2026, present further analysis of the data from the ongoing Phase 1 trial of cemsidomide and dexamethasone.
• In 2H 2027, present initial overall response rate (ORR) data for the MOMENTUM trial.
• In mid-2028, present efficacy and safety for the MOMENTUM trial.
• By year-end 2028, submit new drug application evaluating cemsidomide and dexamethasone for potential accelerated approval in fourth line or later.

Relapsed/Refractory Multiple Myeloma: Second Line or Later

• In Q2 2026, initiate the Phase 1b trial of cemsidomide in combination with elranatamab and provide incremental updates throughout dose escalation.
• In mid-2026, share the plan to initiate an additional Phase 1b trial to evaluate cemsidomide in combination with other anti-myeloma agents.
• In mid-2027, present Phase 1b data from all cohorts evaluating cemsidomide in combination with elranatamab.
• By early 2028, initiate the Phase 3 trial evaluating cemsidomide in combination with a BCMA BiTE.

Early Portfolio: CFT8919

• In Q1 2026, utilize data from the Phase 1 dose escalation trial to inform ex-China clinical development.

Early Portfolio: Internal Discovery Projects Focused on Inflammation, Neuro-inflammation and Neuro-degenerative Diseases

• By year-end 2028, deliver up to three investigational new drug applications.

Early Portfolio: Discovery Collaborations

• Earn additional research milestones and potential licensing fees from collaborations with Merck KGaA, Darmstadt, Germany, Roche and Biogen.
• By year-end 2026, deliver at least one development candidate to a collaboration partner.
• By year-end 2026, advance existing collaborations toward key milestones.

2025 Achievements



Cemsidomide

• Completed enrollment in the Phase 1 trial of cemsidomide and dexamethasone and presented data demonstrating that the two highest dose levels (75 µg and 100 µg) achieved a 40% and 53% ORR, respectively. This compelling anti-myeloma activity in a heavily pretreated patient population reinforces cemsidomide’s potential best-in-class profile.
• Developed a regulatory path incorporating FDA feedback that positions cemsidomide to potentially receive two distinct accelerated approvals in (1) fourth line or later for cemsidomide and dexamethasone, and (2) second line or later for cemsidomide in combination with a BCMA BiTE.
• Selected 100 µg dose for the MOMENTUM trial as the recommended Phase 2 dose after discussions with FDA.

CFT8919

• Advanced the Phase 1 dose escalation trial in China with partner Betta Pharmaceuticals to generate data that will inform C4T’s next steps.

Internal Discovery Pipeline

• Implemented new discovery strategy focused on developing degrader medicines for five novel targets that modulate three clinically validated pathways for inflammation, neuro-inflammation and neuro-degenerative diseases to potentially deliver new therapies with enhanced efficacy for patients with unmet needs. This strategy leverages C4T’s expertise in developing highly catalytic orally bioavailable degraders that penetrate the blood brain barrier to achieve high central nervous system exposures and compelling efficacy in central nervous system models as well as C4T’s ability to control targeted protein levels through finely tuned degrader kinetics.
• Extended capabilities to identify molecular glue degraders for targets with and without G- and RT-loops by utilizing DNA-encoded library (DEL) technology.

About Cemsidomide

Cemsidomide is an investigational, orally bioavailable molecular glue degrader of IKZF1/3, transcription factors that drive multiple myeloma. Data from the Phase 1 trial, which has completed enrollment, show cemsidomide’s differentiated safety and tolerability profile and potentially class-leading anti-myeloma activity that support the potential for durable outcomes.

About the MOMENTUM Trial

MOMENTUM (Multi-center trial Of cemsidoMidE iN relapsed/refracTory mUltiple Myeloma) is a Phase 2, open-label, single-arm study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma. Data from the Phase 1 trial identified 100 µg as the recommended Phase 2 dose. The primary endpoint is overall response rate per International Myeloma Working Group response criteria, as assessed by an independent review committee. Approximately 100 patients who have received at least three prior anti-myeloma regimens that must have included an IKZF1/3 degrader, a proteasome inhibitor, an anti-CD38 antibody, and a T-cell engager or CAR-T therapy will be enrolled in the trial. More information is available at clinicaltrials.gov (NCT07284758).

About Cemsidomide in Combination With Elranatamab (ELREXFIO

^®

)

The Phase 1b trial is designed to evaluate the safety, tolerability and preliminary efficacy of cemsidomide in combination with elranatamab, an FDA-approved B-cell maturation antigen CD3 targeted bispecific antibody. The study will evaluate different cemsidomide dose levels (beginning with 75 µg, with the opportunity to simultaneously explore 50 µg and 100 µg) in patients who have received one to four prior lines of therapy, which must have consisted of at least one IKZF1/3 degrader. Exclusion criteria for patients include those who have received prior treatment with a BCMA-directed T-cell engager or BCMA-directed CAR-T therapy. More information is available at clinicaltrials.gov (NCT07280013).

About Multiple Myeloma

Multiple myeloma (MM) is a rare blood cancer affecting plasma cells. Approximately 36,000 people in the United States are diagnosed with MM each year. Despite advances in treatment, MM remains incurable. Treatment combinations include IKZF1/3 degraders, which are established backbone therapies, across lines of therapy.

About C4 Therapeutics

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO^® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Forward Looking Statements

This press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the predictive capability of our TORPEDO platform in the development of novel, selective, orally bioavailable BiDAC™ and MonoDAC™ degraders; the potential timing, design and advancement of our preclinical studies and clinical trials, including the potential timing for and receipt of regulatory authorization related to clinical trials and other clinical development activities including clinical trial commencement and patient enrollment; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; our ability to replicate interim or early-stage results from our clinical trials in the results obtained when those clinical trials are completed or when those therapies complete later-stage clinical trials; regulatory developments in the United States and foreign countries; the anticipated timing and content of presentations of data from our clinical trials; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that sufficient capital to fund our future operations will not be available to us on acceptable terms or at the times required. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law.

Contacts:

Investors: 
Courtney Solberg
Associate Director, Investor Relations
[email protected]

Media: 
Loraine Spreen 
Senior Director, Corporate Communications & Patient Advocacy 
[email protected]